Tag Archives: biliary tract cancer in

FDA Updates for Week of Sept. 5, 2022

In COVID-19 information, the FDA indicated Eiger’s remedy not supported by knowledge. An advisory committee switched its vote to sure for brand spanking new ALS drug. The FDA accepted Stimufend, a biosimilar to Neulasta, in addition to Imfinzi for biliary tract most cancers, a longer-lasting remedy for frown traces, an oral suspension for gastric ulcers, and generics of… Read More »